scholarly journals Accurate in vivo tumor detection using plasmonic-enhanced shifted-excitation Raman difference spectroscopy (SERDS)

Theranostics ◽  
2021 ◽  
Vol 11 (9) ◽  
pp. 4090-4102
Author(s):  
Pietro Strobbia ◽  
Vanessa Cupil-Garcia ◽  
Bridget M. Crawford ◽  
Andrew M. Fales ◽  
T. Joshua Pfefer ◽  
...  
Keyword(s):  
Tumor Detection ◽  
Difference Spectroscopy

Clinical Evaluation of Radio-Labelled Bleomycin for Tumor Detection

1978 ◽  
Vol 17 (06) ◽  
pp. 238-248
Author(s):  
H. Beekhuis ◽  
M.A.P.C. van de Poll ◽  
A. Versluis ◽  
H. Jurjens ◽  
M.G. Woldring ◽  
...  
Keyword(s):  
Clinical Evaluation ◽  
Acidic Solution ◽  
Tumor Detection ◽  
Neutral Solution ◽  
Normal Tissues ◽  
Patients With Cancer ◽  
Tumor Bearing

Investigations with bleomycin labelled with radionuclides other than 57Co in patients with cancer and in tumor-bearing animals are described. In patients 57Co-bleo appears to be a better tumor-seeking radiopharmaceutical than 111In-bleo, 99mTc-bleo or 197Hg-bleo. This can be explained by a higher stability in vivo and a better tumor-seeking property of 57Co-bleo and less disturbing activity in the cardiac pool and in bone and other normal tissues when assessing the scintigram.Results with 111In-bleo labelled in acidic solution are not essentially different from those with 111In-bleo labelled in neutral solution.Results of 197Hg-bleo are almost identical with those of 197HgCl2 regarding the tumor-seeking effect as well as the distribution in normal tissues and organs. Probably the complex of 197Hg to bleomycin is not stable in vivo. The superiority of 57Co-bleo over 99mTc-bleo, 197Hg-bleo and also over 67Cu-bleo is confirmed by experiments on tumor bearing animals.We may conclude that the indication for use of bleomycin as a tumor-seeking pharmaceutical labelled with 111In, 99mTc, 197Hg or 67Cu seems to be very limited.

Trends in Nanotechnology for in vivo Cancer Diagnosis: Products and Patents

2020 ◽  
Vol 26 (18) ◽  
pp. 2167-2181
Author(s):  
Tatielle do Nascimento ◽  
Melanie Tavares ◽  
Mariana S.S.B. Monteiro ◽  
Ralph Santos-Oliveira ◽  
Adriane R. Todeschini ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Quantum Dots ◽  
Magnetic Resonance ◽  
Metal Nanoparticles ◽  
Cancer Diagnosis ◽  
Imaging Techniques ◽  
Tumor Detection ◽  
Abnormal Growth ◽  
Pharmaceutical Nanotechnology

Background: Cancer is a set of diseases formed by abnormal growth of cells leading to the formation of the tumor. The diagnosis can be made through symptoms’ evaluation or imaging tests, however, the techniques are limited and the tumor detection may be late. Thus, pharmaceutical nanotechnology has emerged to optimize the cancer diagnosis through nanostructured contrast agent’s development. Objective: This review aims to identify commercialized nanomedicines and patents for cancer diagnosis. Methods: The databases used for scientific articles research were Pubmed, Science Direct, Scielo and Lilacs. Research on companies’ websites and articles for the recognition of commercial nanomedicines was performed. The Derwent tool was applied for patent research. Results: This article aimed to research on nanosystems based on nanoparticles, dendrimers, liposomes, composites and quantum dots, associated to imaging techniques. Commercialized products based on metal and composite nanoparticles, associated with magnetic resonance and computed tomography, have been observed. The research conducted through Derwent tool displayed a small number of patents using nanotechnology for cancer diagnosis. Among these patents, the most significant number was related to the use of systems based on metal nanoparticles, composites and quantum dots. Conclusion: Although few systems are found in the market and patented, nanotechnology appears as a promising field for the development of new nanosystems in order to optimize and accelerate the cancer diagnosis.

Use of in vivo near-infrared laser confocal endomicroscopy with indocyanine green to detect the boundary of infiltrative tumor

2011 ◽  
Vol 115 (6) ◽  
pp. 1131-1138 ◽  
Author(s):  
Nikolay L. Martirosyan ◽  
Daniel D. Cavalcanti ◽  
Jennifer M. Eschbacher ◽  
Peter M. Delaney ◽  
Adrienne C. Scheck ◽  
...  
Keyword(s):  
Indocyanine Green ◽  
Tumor Cells ◽  
Near Infrared ◽  
Tumor Resection ◽  
Tumor Detection ◽  
Normal Brain ◽  
Tumor Margins ◽  
Confocal Endomicroscopy ◽  
Infiltrative Tumor

Object Infiltrative tumor resection is based on regional (macroscopic) imaging identification of tumorous tissue and the attempt to delineate invasive tumor margins in macroscopically normal-appearing tissue, while preserving normal brain tissue. The authors tested miniaturized confocal fiberoptic endomicroscopy by using a near-infrared (NIR) imaging system with indocyanine green (ICG) as an in vivo tool to identify infiltrating glioblastoma cells and tumor margins. Methods Thirty mice underwent craniectomy and imaging in vivo 14 days after implantation with GL261-luc cells. A 0.4 mg/kg injection of ICG was administered intravenously. The NIR images of normal brain, obvious tumor, and peritumoral zones were collected using the handheld confocal endomicroscope probe. Histological samples were acquired from matching imaged areas for correlation of tissue images. Results In vivo NIR wavelength confocal endomicroscopy with ICG detects fluorescence of tumor cells. The NIR and ICG macroscopic imaging performed using a surgical microscope correlated generally to tumor and peritumor regions, but NIR confocal endomicroscopy performed using ICG revealed individual tumor cells and satellites within peritumoral tissue; a definitive tumor border; and striking fluorescent microvascular, cellular, and subcellular structures (for example, mitoses, nuclei) in various tumor regions correlating with standard clinical histological features and known tissue architecture. Conclusions Macroscopic fluorescence was effective for gross tumor detection, but NIR confocal endomicroscopy performed using ICG enhanced sensitivity of tumor detection, providing real-time true microscopic histological information precisely related to the site of imaging. This first-time use of such NIR technology to detect cancer suggests that combined macroscopic and microscopic in vivo ICG imaging could allow interactive identification of microscopic tumor cell infiltration into the brain, substantially improving intraoperative decisions.

Tumor Detection in vivo with Optical Spectroscopy

2005 ◽  
Author(s):  
V. Misic ◽  
B.A. Winey ◽  
H. Liu ◽  
L. Liao ◽  
P. Okunieff ◽  
...  
Keyword(s):  
Optical Spectroscopy ◽  
Tumor Detection

scholarly journals Shifted-excitation Raman difference spectroscopy for in vitro and in vivo biological samples analysis

2010 ◽  
Vol 1 (2) ◽  
pp. 617 ◽  
Author(s):  
Mário Augusto da Silva Martins ◽  
Dayana Gonçalves Ribeiro ◽  
Edson Aparecido Pereira dos Santos ◽  
Airton Abrahão Martin ◽  
Adriana Fontes ◽  
...  
Keyword(s):  
Biological Samples ◽  
Difference Spectroscopy

In vivo breast tumor detection using transient elastography

2003 ◽  
Vol 29 (10) ◽  
pp. 1387-1396 ◽  
Author(s):  
J. Bercoff ◽  
S. Chaffai ◽  
M. Tanter ◽  
L. Sandrin ◽  
S. Catheline ◽  
...  
Keyword(s):  
Breast Tumor ◽  
Transient Elastography ◽  
Tumor Detection

scholarly journals Multimode optical imaging for translational chemotherapy: in vivo tumor detection and delineation by targeted gallium corroles

2011 ◽  
Author(s):  
Jae Youn Hwang ◽  
Zeev Gross ◽  
Harry B. Gray ◽  
Lali K. Medina-Kauwe ◽  
Daniel L. Farkas
Keyword(s):  
Optical Imaging ◽  
Tumor Detection

Shifted excitation resonance Raman difference spectroscopy system suitable for the quantitative in vivo detection of carotenoids in human skin

2018 ◽  
Vol 15 (11) ◽  
pp. 115601 ◽  
Author(s):  
Marcel Braune ◽  
Martin Maiwald ◽  
Maxim E Darvin ◽  
Bernd Eppich ◽  
Bernd Sumpf ◽  
...  
Keyword(s):  
Human Skin ◽  
Resonance Raman ◽  
Difference Spectroscopy ◽  
In Vivo Detection ◽  
Spectroscopy System
Sign in / Sign up

Export Citation Format

Share Document